


Clinical Cases in **GLAUCOMA** *An Evidence-based Approach*



Shibal Bhartiya • Parul Ichhpujani



Contents

1. Ocular Hypertension

1

Shibal Bhartiya, Parul Ichhpujani

-  **Case 1:** No treatment required for ocular hypertension 1
-  **Case 2:** Treatment for ocular hypertension required depending on age 1
-  **Case 3:** Treatment for ocular hypertension required depending on central corneal thickness 1
 - *How to manage this patient if his central corneal thickness measured 480 microns? or 610 microns?* 2
-  **Case 4:** Treatment for ocular hypertension required depending on dv and high peak pressures 2
 - *Investigations* 3
 - *Follow-up Protocol* 3
 - *Commentary* 3

2. Glaucoma Suspect

6

Augusto Vieira, Tiago Prata, Fabio Kanadani, Syril Dorairaj

Who is a Glaucoma Suspect? 6

-  **Case 1:** Strong risk factors 6
-  **Case 2:** Disc hemorrhage 6
-  **Case 3:** Low central corneal thickness 7
-  **Case 4:** Disc asymmetry 7
-  **Case 5:** Diurnal variation of intraocular pressure 8
-  **Case 6:** Glaucoma suspect at a young age 9

Literature review 10

- *Intraocular Pressure* 10
- *Optic Nerve Head* 10
- *Central Corneal Thickness* 10
- *Risk Factors for Glaucoma* 11

3. Primary Open-Angle Glaucoma

13

Shibal Bhartiya, Parul Ichhpujani

-  **Case 1:** No treatment required for early primary open-angle glaucoma 13
-  **Case 2:** Treatment for early primary open-angle glaucoma required depending on age 14
-  **Case 3:** Treatment for early primary open-angle glaucoma required depending on central corneal thickness 16
-  **Case 4:** Treatment for moderate primary open-angle glaucoma requiring more than one antiglaucoma medication 19
-  **Case 5:** Treatment of severe primary open-angle glaucoma requiring surgery since not controlled on maximal tolerable medical therapy 19
-  **Case 6:** Treatment of severe primary open-angle glaucoma requiring surgery at first diagnosis due to severe visual field loss 20

Investigations 20
 Follow-up Protocol 21
 What is the Natural Course of the Disease? 21
 Broad Guidelines for Management 22

4. **Medical Therapy: Monotherapy, Fixed Combinations, Side Effects and Quality of Life Implications** 25

Simon Skalicky, Ivan Goldberg

-  **Case 1:** Monotherapy 25
-  **Case 2:** Fixed drug combinations 25
-  **Case 3:** Side effects and quality of life 28

- *Investigations* 29
- *Follow-up Protocol* 29
- Brief Review of Literature 29
- Summary 30
- *Pharmacological Classes* 30
- *Fixed Combination Medications* 30
- *Preserved versus Preservative Free Preparations* 30
- *Drop Instillation Technique (Instructions for New Patients)* 31
- *Commentary* 31

5. **Laser Trabeculoplasty** 33

Shibal Bhartiya, Parul Ichhpujani

Indications 33
 Contraindications 34

-  **Case 1:** SLT for drug induced ocular surface disease 34
-  **Case 2:** SLT for patient unable to instill drugs 34
-  **Case 3:** SLT for angle closure 34
-  **Case 4:** Repeat SLT 35
- *Repeatability of Selective Laser Trabeculoplasty* 35
- *Selective Laser Trabeculoplasty versus Argon Laser Trabeculoplasty* 35

6. **Angle-Closure Glaucoma** 36

Sushmita Kaushik, Pankaj Kataria

- Stages of Angle-Closure Disease 36
- *Primary Angle-Closure Suspect* 36
 - *Primary Angle Closure* 36
 - *Primary Angle-Closure Glaucoma* 36
 - *Acute Angle Closure* 36
- Epidemiology 37
- Risk Factors 37
- *Demographic Factors* 37
 - *Anatomic Factors* 37
 - *Precipitating Factors* 38

Diagnosis 38

- *External Examination* 38
- *Penlight Examination* 38
- *Slit-Lamp Examination* 38
- *Gonioscopy* 38
- *Other Imaging Techniques* 39

Management 39

- *Primary Angle-Closure Suspect* 39
- *Primary Angle Closure* 39
- *Primary Angle-Closure Glaucoma* 39

7A. Trabeculectomy versus Tube

41

Giovanna Casale-Vargas, Oscar Albis-Donado, Gabriel Lazcano-Gómez



Case 1: Trabeculectomy with mitomycin C 41



Case 2: Trabeculectomy with biodegradable collagen matrix implant, ologen 41



Case 3: EX-PRESS mini glaucoma shunt 41



Case 4: Primary Ahmed valve implant 44



Case 5: Ahmed valve implant and neovascular glaucoma 44

Investigations 44

- *Follow-up Protocol* 44

Brief Review of Literature 45

Summary 46

7B. Choice of Surgery: Nonpenetrating Deep Sclerectomy

48

Sylvain Roy, André Mermoud



Case 1: Primary open-angle glaucoma 48



Case 2: Pseudoexfoliative glaucoma 49



Case 3: Normal tension glaucoma 49



Case 4: Angle-closure glaucoma and neovascular glaucoma 50



Case 5: Traumatic glaucoma 50



Case 6: Uveitic glaucoma 51



Case 7: Pigmentary glaucoma 52

Investigations 52

Follow-up Protocol 53

Brief Review of Literature 53

Summary 53

7C. Transscleral Cyclophotocoagulation

55

Monica Gandhi, Suneeta Dubey, Julie Pegu, Nishtha Singh

Mechanism of Action 55

Indications 55

-  **Case 1:** TSCPC for NVG 56
-  **Case 2:** TSCPC for postkeratoplasty glaucoma 57
-  **Case 3:** TSCPC for failed glaucoma surgery 57
- How to Use a G-Probe? 58
- How many Quadrants to Treat? 58
- Complications 58

7D. Endocyclophotocoagulation

59

Parul Ichhpujani, Shibal Bhartiya

- Indications 59
- Contraindications 60
- Technique 60
 - *Equipment* 60
-  **Case 1:** Endocyclophotocoagulation with phacoemulsification 60
-  **Case 2:** Endocyclophotocoagulation in angle closure 61
-  **Case 3:** Endocyclophotocoagulation-plus 61

8. Complications after Trabeculectomy

62

Oana Stirbu, Jorge Vila Arteaga

-  **Case 1:** Overfiltering bleb 62
-  **Case 2:** Corneal dellen 62
-  **Case 3:** Wound leak 63
-  **Case 4:** Fistula obstruction 64
-  **Case 5:** Postoperative hyphema 64
-  **Case 6:** Malignant glaucoma 65
-  **Case 7:** Blebitis and bleb-related endophthalmitis 65
-  **Case 8:** Ischemic bleb 66
-  **Case 9:** Tenon cyst 66
-  **Case 10:** Dysesthetic bleb 67

9. Tube Complications

68

Nadia Ríos-Acosta, Oscar Albis-Donado

-  **Case 1:** Hypotony resolved without treatment 68
-  **Case 2:** Hypotony that requires treatment 68
-  **Case 3:** Tube exposure 68
-  **Case 4:** Aqueous misdirection 69
-  **Case 5:** Corneal decompensation 69
-  **Case 6:** Tube blockage 70

Follow-up Protocol	70
Brief Review of Literature	70
Shallow or Flat Anterior Chamber	71
Hypertensive Phase	72
Corneal Decompensation	73
Motility Disorders	73
Tube Exposure	73
Endophthalmitis	73
Complications of Ahmed Valve Implant on Children	73

10. Complications of Nonpenetrating Deep Sclerectomy 75

Sylvain Roy, André Mermoud

 Case 1: Rupture of the thin trabeculo-Descemet's membrane	75
 Case 2: Leak of the filtering bleb (Seidel's sign)	76
 Case 3: Hypotony	77
 Case 4: Bleb fibrosis and encystment of the bleb	77
 Case 5: Secondary rise in the intraocular pressure	78
Investigations	78
Follow-up Procedure	79
Brief Review of Literature	79
Summary	79

11. Complications of Newer Surgeries 80

Youssef Abdelmassih, Sylvain el-Khoury, Ziad Khoeir, Tarek Shaarawy

Classification	80
Complications	80
 Case 1: Medical management of shallow anterior chamber after EX-PRESS glaucoma filtration device	81
 Case 2: XEN Gel-stent implant combined with cataract surgery	81
 Case 3: CyPass Micro-stent implantation with postoperative hyphema	81
 Case 4: Hypertony following iStent implantation	83
Management of Complications	84
• Intraocular Pressure Increase	84
• Hyphema	84
• Hypotony/Shallow Anterior Chamber	84
• Stent Occlusion	84
• Bleb Leak	85

12A. Glaucoma in Children 86

Alejandra Hernandez-Oteyza, Oscar Albis-Donado

 Case 1: Primary congenital glaucoma	86
 Case 2: Juvenile open-angle glaucoma	86
 Case 3: Glaucoma associated with nonacquired ocular anomalies	87
 Case 4: Glaucoma associated with nonacquired systemic disease or syndrome	87

Investigations	91
• General Appearance/General Examination	91
• Visual Acuity and Refraction	91
• Tonometry	91
• Corneal Diameter Measurement	91
• Gonioscopy	91
• Optic Nerve Assessment	92
• Ultrasound	92
• Anterior Segment Images	92
• Automated Perimetry	92
• Ocular Coherence Tomography with Retinal Nerve Fiber Layer and Ganglion Cell Complex Analysis	92
Follow-up Protocol	92
Summary	92

12B. Postrefractive Surgery Glaucoma

96

Mona Khurana, Aditya Neog

Investigations	96
• Prerefractive Surgery Screening	96
• Postrefractive Surgery	96
 Case 1: Steroid-induced glaucoma postrefractive surgery	97
 Case 2: Primary open-angle glaucoma in the postrefractive surgery period	97
 Case 3: Late detection of secondary glaucoma following laser-assisted in-situ keratomileusis	97
 Case 4: Bilateral acute angle-closure glaucoma following hyperopic laser-assisted in-situ keratomileusis	98
 Case 5: Unilateral acute angle-closure glaucoma following phakic intraocular lens implantation	98
Management of Glaucoma	98
• Medical Management	98
• Laser	98
• Surgery	98
• Follow-up	99
Review of Literature	99
• Intraocular Pressure Measurement	99
• Steroid Response	99
• Acute Optic Neuropathy Postlaser-assisted in-situ Keratomileusis	99
• Acute Angle-Closure Glaucoma	100

12C. Glaucoma after Vitreoretinal Surgery

102

Gowri J Murthy, Praveen R Murthy

Classification	102
Risk Factors for Postvitrectomy Glaucoma	102
 Case 1: Postsilicone oil-removal glaucoma	102
 Case 2: Postoperative steroid-induced glaucoma-managed medically	104
 Case 3: Multiple mechanisms for raised intraocular pressure requiring surgical management	105
 Case 4: Iris bombe causing secondary angle closure and silicone oil overfill	107
 Case 5: Silicone oil-induced glaucoma in a high myope managed with silicone oil removal with endoscopic cyclophotocoagulation	108

Investigations	110
Management	112
• Medical Management	112
• Laser Iridotomy	113
• Surgical Management	113
Follow-up Protocol	114
Brief Review of Literature	114
Summary	114

12D. Neovascular Glaucoma

117

Jasleen Dhillon

Etiopathogenesis	117
• Diabetes	117
• Ischemic Central Retinal Vein Occlusion	117
• Carotid Artery Obstructive Disease	117
Clinical Features	117
Management	118
• Grades of Neovascular Glaucoma	118
• Panretinal Photocoagulation	118
• Antivascular Endothelial Growth Factor	118
• Medical Management of Neovascular Glaucoma	119
• Surgical Management of Glaucoma	119
 Case 1: NVG in a diabetic with PDR	119
 Case 2: NVG in vascular occlusion	119
 Case 3: Anti VEGF for NVG	120
 Case 4: PRP for NVG	120
 Case 5: PPV with GDD for NVG	121
 Case 6: TSCPC for NVG	121

12E. Cataract and Glaucoma

123

M Chockalingam

 Case 1: Cataract surgery alone in an eye with no prior glaucoma filtration surgery	123
 Case 2: Cataract and glaucoma surgery	123
 Case 3: Sequential glaucoma and cataract (cataract surgery post-trabeculectomy)	125
Workup of a Patient before Decision Making and Surgery	126
Follow-up Protocol	126
Key Points to be Considered in Decision-making	127
• Cataract Surgery Alone with No Previous Glaucoma Filtration Surgery	128
• Combined Cataract and Glaucoma Surgery	129
• Two-staged Cataract and Glaucoma Surgery	130

12F. Compliance

131

Shibal Bhartiya, Parul Ichhpujani, Suresh Kumar

 Case 1: White coat adherence	131
 Case 2: Drug induced nocturnal hypotension	133
 Case 3: Drug induced ocular surface disease	134

13. Informed Consents**137***Shibal Bhartiya, Parul Ichhpujani, Suresh Kumar*

Who can Give Consent? 137

Ethics of Consent 138

- *Exemptions to Disclosure* 138

Special Consents 138

- *Informed Consent for Trabeculectomy* 138
- *Informed Consent for Glaucoma Drainage Implant Surgery* 139
- *Informed Consent for Cataract Surgery* 140
- *Informed Consent Form for Neodymium-doped: Yttrium Aluminum Garnet Laser Capsulotomy* 141
- *Neodymium-doped: Yttrium Aluminum Garnet Laser Iridotomy* 142
- *Informed Consent for Selective Laser Trabeculoplasty* 142
- *Informed Consent for Diode Laser Cyclophotocoagulation* 143

14A. How to Overcome Imaging Artifacts and Prevent Misinterpretation of Imaging Results**145***Gábor Holló*

Background 145

Technical Evidences 145

Interpretation Evidences 146

- *Parameter Types and their Practical Clinical Value* 147

**Case 1:** Red disease due to healthy macrodiscs 148**Case 2:** Green disease due to macula edema 148**Case 3:** Blink artifact 149**Case 4:** Segmentation error due to a vitreoretinal surface abnormality 150**Case 5:** Segmentation error caused by a vitreous floater 150

How to Avoid Misinterpretation of RNFLT and Inner Macular Retina

Thickness Changes during Long-term Follow-up? 151

Summary 152

14B. Sources of Errors While Interpreting Perimetry**153***Parul Ichhpujani, Sahil Thakur, Suresh Kumar***Case 1:** Error due to pupil size 153**Case 2:** Error due to drooping lid 154**Case 3:** Error due to incorrect ocular aid 154**Case 4:** Error due to fatigue 155**14C. Sources of Errors While Performing and Interpreting Tonometry****159***Nikhil S Choudhary, Paaraj Dave, Parul Ichhpujani*

Goldmann Applanation Tonometer 159

- *How to Perform Applanation Tonometry using Goldmann Applanation Tonometer?* 159
- *Procedure and Instrumentation* 159
- *Common Sources of Error and Ways to Avoid Them* 160

- *What to Do in a Patient with Marked Astigmatism?* 160
- *How to Detect Calibration Error of the Goldmann Applanation Tonometer?* 162
- Schiotz Indentation Tonometer 162
 - *How to Perform Indentation Tonometry using Schiotz's Tonometer?* 163
 - *Sources of Errors with a Schiotz Indentation Tonometer* 163
 - *Pearls for the Care of Schiotz Tonometer* 163
- Noncontact Tonometer 163
 - *How to Perform Noncontact Tonometry?* 164
 - *Sources of Errors with Noncontact Tonometer* 164

15A. Clinical Trials in Glaucoma

165

Suneeta Dubey, Madhu Bhoot, Nishtha Singh, Dushyant Sharma, Monica Gandhi

- Ocular Hypertension Treatment Study 165
- Early Manifest Glaucoma Trial 166
- Collaborative Initial Glaucoma Treatment Study 167
- Collaborative Normal-tension Glaucoma Study 168
- Advanced Glaucoma Intervention Study 169
- Glaucoma Laser Trial 170
- Trabeculectomy versus Tube Study 170
- Ahmed-Baerveldt Comparison Study 172
- Ahmed versus Baerveldt Study 173

15B. Basics of a Trial Design for Glaucoma

175

Shibal Bhartiya, Parul Ichhpujani

- Levels of Evidence for Clinical Application (Choosing the Study Design) 175
- Definition of Disease (Type and Severity) 175
- Definition of Cohort Demographics 177
- Definition of Data Points Evaluated and End Point 177
 - *Baseline Intraocular Pressure Measurement* 177
 - *Visual Acuity* 177
 - *Visual Field* 177
 - *Ocular Hypotensive Medication* 178
- Follow-up and Reporting Time Windows 178
- Evaluation (Criteria for Success and Failure) 178
 - *For Diagnostic Modalities* 178
 - *For Therapeutic Modalities (Surgical and Medical)* 178
- Ethical Considerations 179
 - *Randomization to Nontreatment Arm* 179
 - *Clear Definition of Acceptable Outcomes* 179
 - *Informed Consent* 179
 - *Approval from Institutional Review Board or Ethics Committee* 179
 - *Adherence to Tenets of Declaration of Helsinki* 179
 - *Declaration of Sources of Funding (Financial and Nonfinancial Support and Conflicts of Interest)* 179
- Statistical Considerations 179
 - *Calculation of Sample Size* 179
 - *Statistical Significance* 179
 - *Software for Data Analysis* 179
 - *Randomization* 179
 - *Data Analysis* 179
 - *Eyes versus Patients* 179

- *Interim Analysis and Stopping Rules* 180
- *Data Representation* 180
- Special Considerations 180
 - *Methods of Economic Evaluation of Glaucoma* 180
 - *Methods of Quality of Life Assessments* 180

CHAPTER 3

Primary Open-Angle Glaucoma

Shibal Bhartiya, Parul Ichhpujani

INTRODUCTION

Primary open-angle glaucoma (POAG) is a chronic progressive optic neuropathy defined by an open, normal appearing anterior chamber angle and raised intraocular pressure (IOP), with no other underlying disease, in the presence of the characteristic cupping of the optic disc with corresponding visual field defects, due to retinal ganglion cell loss. If there is an identifiable underlying cause for raised IOP, this is termed secondary glaucoma. If the IOP is within normal limits, this is termed normal-tension glaucoma (NTG) or low-tension glaucoma (LTG).

Case 1: No treatment required for early primary open-angle glaucoma

Mr X, a 72-year-old gentleman, was found to have persistently elevated IOPs on three visits [oculus uterque (OU) 23, 24, 24 mm Hg]. The cup-to-disc (C:D) ratio was 0.5:1 and 0.45:1 with slightly eccentric cup with inferior > superior > nasal > temporal (ISNT) maintained (Fig. 3.1). The visual field [humphrey visual field (HVF) 30-2, Swedish Interactive Threshold Algorithms standard] showed early changes suggestive of glaucomatous damage (Fig. 3.2). The central corneal thickness (CCT) was 531 microns and




Fig. 3.1: Vertical cup-to-disc ratio of 0.5:1 and 0.45:1, with slightly eccentric cup with ISNT rule maintained.




Fig. 3.2: Early glaucomatous damage in left eye.

522 microns for the right and left eyes, respectively. The retinal nerve fiber layer (RNFL) optical coherence tomography (OCT) (CIRRUS) did show early RNFL thinning (Fig. 3.3), and gonioscopy showed wide open angles with no pigmentation. He had a coronary artery bypass surgery 6 years ago and was a hypertensive on medication. There was no family history of glaucoma or blindness.

Risks and benefits of initiating glaucoma therapy were discussed with Mr X, keeping in mind the following:

- Life expectancy
- Early field defects
- Slightly elevated eye pressures
- Pre-existing dry eye due to old age which would probably get exacerbated with antiglaucoma medication.

He agreed that deferring treatment was better than initiating treatment immediately on diagnosis. He was asked to follow-up every 4–6 months for 2 years. His visual fields did not show any significant change on serial monitoring. The visual field evaluation was thereafter scheduled for once a year.

Case 2: Treatment for early primary open-angle glaucoma required depending on age

Ms A, a 53-year-old lady, was found to have persistently elevated IOPs on three visits (OU 28, 24, 25 mm Hg) with a diurnal fluctuation of 8 mm Hg in both the eyes. The cup: disc ratio was 0.6:1 and 0.55:1 with a focal neuroretinal rim thinning. The visual field showed early changes suggestive of glaucomatous damage (Fig. 3.4). The CCT was 532 and 526 for the right and left eyes, respectively. The RNFL OCT (Cirrus) showed RNFL thinning (Fig. 3.5), and gonioscopy showed wide open angles. She had no comorbidities. There was no family history of glaucoma or blindness.

Risks and benefits of initiating glaucoma therapy were discussed with Ms A, keeping in mind the following:

- Long-life expectancy
- Early field defects
- Slightly elevated eye pressures.

ONH and RNFL OU Analysis: Optic Disc Cube 200 × 200 OD ● OS ●




Fig. 3.3: Early RNFL thinning in the left eye on SDOCT.
(ONH: Optic nerve head; RNFL: Retinal nerve fiber layer; SDOCT: Spectral domain optical coherence tomography).




Fig. 3.4: Early glaucomatous visual field defects.

She agreed that it was better to initiate treatment immediately on diagnosis. She was prescribed travoprost eye drops, one drop each eye, once at bedtime in both eyes and asked to follow-up after 6 weeks. The IOP was found to be 18 mm Hg OU with a diurnal fluctuation of 4 mm Hg and 5 mm Hg, respectively. She was advised to repeat fields after 6 months, and no significant change on serial monitoring was noted for over 2 years. She was advised to continue drops as prescribed.

Case 3: Treatment for early primary open-angle glaucoma required depending on central corneal thickness

Mrs X, a 68-year-old lady was found to have persistently elevated IOPs on three visits (OU 24, 25, 25 mm Hg), with a diurnal fluctuation of 9 mm Hg and 8 mm Hg, respectively. The cup: disc ratio was 0.7 and 0.65 with corresponding early changes on visual fields suggestive of glaucomatous damage. The CCT was 472 μ and 482 μ for the right and left eyes, respectively. The RNFL OCT (CIRRUS) showed early RNFL thinning (Fig. 3.6), and gonioscopy showed

wide open angles. She had no comorbidities. There was no family history of glaucoma or blindness.

Risks and benefits of initiating glaucoma therapy were discussed with Ms X, keeping in mind the following:

- Life expectancy
- Early field defects
- Elevated eye pressures
- Increased chances of progression in CCT less than 520 microns.

She agreed that it was better to initiate treatment immediately on diagnosis. She was prescribed bimatoprost eye drops, one drop each eye, once at bedtime in both eyes and asked to follow-up after 6 weeks. The IOP was found to be 16 OU with a diurnal fluctuation of 4 mm Hg and 3 mm Hg, respectively. She was advised to repeat fields after 6 months and no significant change on serial monitoring for over 2 years. She complained of dryness in both eyes and was prescribed carboxymethylcellulose eye drops, thrice a day, which obviated her symptoms. She was advised to continue drops as prescribed, and the visual field evaluation was thereafter scheduled for once a year.

ONH and RNFL OU Analysis: Optic Disc Cube 200 × 200




Fig. 3.5: Flattening of retinal nerve fiber layer humps on SDOCT.
(ONH: Optic nerve head; RNFL: Retinal nerve fiber layer; SDOCT: Spectral domain optical coherence tomography).


ONH and RNFL OU Analysis: Optic Disc Cube 200 × 200 **OD** ● **OS** ●

Fig. 3.6: SDOCT showing thinning of retinal nerve fibre layer in right eye.
(ONH: Optic nerve head; RNFL: Retinal nerve fiber layer; SD OCT: Spectral domain optical coherence tomography).




Fig. 3.7: Vertical cup-to-disc ratio of 0.85 and 0.7, with broken ISNT rule.

Case 4: Treatment for moderate primary open-angle glaucoma requiring more than one antiglaucoma medication

Mr X, a 67-year-old gentleman, was diagnosed with moderate POAG with persistently elevated IOPs on two visits (OD and OS: 34, 35 mm Hg) with a diurnal fluctuation of 8 mm Hg OU. The C:D ratio was 0.85 and 0.7 with broken ISNT rule and corresponding moderate glaucomatous damage on visual fields (Fig. 3.7). The CCT was 522 and 512 for the right and left eyes, respectively. The RNFL OCT also showed flattening of RNFL humps and gonioscopy showed wide open angles.

Risks and benefits of initiating glaucoma therapy were discussed with him, keeping in mind the following:

- Life expectancy
- Field defects
- Elevated eye pressures
- Increased chances of progression in CCT less than 520 microns.

He agreed that it was better to initiate treatment immediately on diagnosis and to try a single medication for efficacy and safety rather than combination therapy. He was prescribed bimatoprost eye drops, one drop each eye, once at bedtime in both eyes, and asked to follow-up after 2 days. The IOP was found to be 24 mm Hg OU, and he was

thereafter asked to report for a water drinking test (WDT) after 4 weeks. The IOP was found to be 22 mm Hg OU with a diurnal fluctuation of 4 mm Hg and 6 mm Hg, respectively.

Since the target IOP was not reached with one drug, a fixed dose combination of bimatoprost and timolol was advised, once at bedtime. The fact that the efficacy of timolol is less at night was weighed against the chances of reduced compliance with addition of a second bottle. This was discussed with the patient and he preferred to use a fixed-dose combination (FDC) in view of convenience of use. At 4 weeks follow-up, the IOP was found to be 16 mm Hg OU with a diurnal fluctuation of 3 mm Hg and 5 mm Hg, respectively.

He was advised to repeat fields after 4 months and no significant change was observed on serial monitoring for over 2 years. He was advised to continue drops as prescribed and the visual field evaluation was thereafter rescheduled for once every 6 months, with a RNFL OCT performed annually.

Case 5: Treatment of severe primary open-angle glaucoma requiring surgery since not controlled on maximal tolerable medical therapy

Mr X, a 69-year-old pseudophakic gentleman, was on treatment for advanced POAG over the last 6 years with persistently elevated IOPs on two visits (OD and OS: 26, 25




Fig. 3.8: Vertical cup-to-disc ratio of 0.9 OU with a marked concentric neuroretinal rim loss.

with a diurnal fluctuation of 8 mm Hg OU on treatment [bimatoprost harmonized system (HS), brimonidine + timolol FDC BD, brinzolamide BD]. The C:D ratio was 0.9 OU with a marked concentric neuroretinal rim (NRR) loss (Fig. 3.8). The visual field could not be performed to poor visual acuity. The CCT was 532 and 541 for the right and left eyes, respectively. Risks and benefits of glaucoma surgery were discussed with him and he agreed that it was better to go ahead with surgery since even maximal topical therapy was insufficient to control his IOP.

He was advised trabeculectomy augmented with mitomycin C, for the right eye first, followed by the left eye. After surgery his IOP was 16 and 18, respectively, without any medication, despite release of the releasable sutures in the early postoperative period. He required the addition of a prostaglandin analog (bimatoprost HS, OU) to achieve target pressure of 11 mm Hg and 12 mm Hg, respectively. He attained the target IOP and then he was advised to continue drops as prescribed.

Case 6: Treatment of severe primary open-angle glaucoma requiring surgery at first diagnosis due to severe visual field loss

Mrs X, a 65-year-old pseudophakic lady with diabetes, presented to the outpatients clinic with IOP of 32 both eyes, and a near total optic atrophy in the right eye, and a C:D ratio of 0.85 OD and 0.9:1 OS. Her best-corrected visual acuity in right eye was 6/60 and 3/60 in the left eye.

A 24-2 HVF OD was predictably showing a severe visual field loss encroaching fixation and a 10-2 test was there after advised, which showed split fixation. Visual field in left eye could not be performed due to poor vision.

The possibility of imminent visual loss was discussed with her and the risks and benefits of primary surgery were also discussed with the patient and her family. Given the advanced stage of glaucomatous damage, high IOP, it was decided to perform a primary trabeculectomy on both eyes at an interval of 4 weeks. In the interim, she was referred to an internist for euglycemic control and prescribed bimatoprost HS, brimonidine + timolol FDC BD and brinzolamide BD eye drops for both eyes. After surgery, her IOP was 12 and 11, respectively, without any medication following release of the releasable sutures in the early postoperative period for the left eye only. A repeat field was ordered after 4 months for the right eye and no significant change was observed on serial monitoring for over a year.

INVESTIGATIONS

Every patient of glaucoma requires a careful and comprehensive eye examination. Mandatory tests include:

- **Visual Acuity and Refraction**
- **Tonometry (Applanation)**

On at least two different occasions, at different times of the day, with IOP more than 21 mm Hg is mandatory for diagnosing POAG. IOP less than 21 mm Hg does not rule out glaucoma.

- **Slit Lamp Examination**

A through slit lamp evaluation is mandatory to rule out any secondary reasons for elevated IOP.

- **Gonioscopy**

Anatomically normal and open angles are mandatory for diagnosing POAG.

- **Optic Nerve Assessment**

A dilated assessment of the optic nerve head (ONH) is essential together with a red-free evaluation of the peripapillary RNFL. The ONH can be documented using a hand-drawn, labeled diagram (special emphasis on cup/disc ratio, notching, RNFL defects and/or hemorrhage) and/or a clinical picture. A color photo and a red-free photo of the ONH are essential for serial follow-up.

- **Visual Field Testing**

Reliable visual fields provide a baseline for future follow-up. The first visual fields are usually discarded as unreliable or having a learning curve.

- **Central Corneal Thickness (Pachymetry)**

It is an adjunct that helps to make therapeutic decisions.

- **Imaging of the Optic Nerve with Retinal Nerve Fiber Layer Analysis**

Imaging of the optic nerve with RNFL analysis (ocular coherence tomography, Heidelberg retinal tomography or scanning laser polarimetry) provides a statistical comparison with the normative database, thereby providing additional objective information for subsequent management.

In addition, the following tests, if performed, help in managing the condition better in case the facilities exist and are affordable to the patient.

- **Diurnal Variation of Intraocular Pressure**

A 24-hour diurnal variation of IOP includes IOP recording every 2 hours, preferably using the same Goldmann applanation tonometry, by the same observer, whenever possible. A diurnal variation of more than 8 mm over 24 hours is considered indicative of glaucoma. Diurnal variation of IOP curve may provide additional information and influence treatment protocol.

- **Water Drinking Test**

A WDT with 10 mL/kg body weight of water over 5 minutes may be performed as a surrogate for diurnal variation of IOP to provide a rough idea of IOP peaks and fluctuation.

- Stereo-optic disc photographs to confirm normal optic nerve parameters and document baseline.

Table 3.1: Severity of primary open-angle glaucoma.

Severity	Description
Mild	GON + normal visual field on SAP
Moderate	GON + VFD in one hemifield, but not within 5° of fixation on SAP
Severe	GON + VFD in both hemifields ± loss within 5° of fixation in at least one hemifield on SAP

(GON: Glaucomatous optic neuropathy; VFD: Visual field defect; SAP: Standard automated perimetry).

Source: American Academy of Ophthalmology Glaucoma Panel. (2010). Preferred practice pattern guidelines. Primary open-angle glaucoma. [online] Available from www.aaofpp.org/ppp. [Accessed July, 2016].

- Based on the above investigations POAG severity can be graded as mentioned in Table 3.1.

FOLLOW-UP PROTOCOL

Follow-up protocol is to be customized to the individual patient depending on the risk of developing glaucoma, risk factors present and whether treatment has been initiated or not. Initially, a follow-up may be scheduled after 4–6 weeks for safety and efficacy checks after initiating topical anti-glaucoma therapy. Six fields, done over 2 years, are required for establishing the rate of progression.

Repeat visual field and optic nerve testing may be performed annually or sooner if changes are suspected.

WHAT IS THE NATURAL COURSE OF THE DISEASE?

- Of approximately 1.2 million RGC at birth, about 25% are naturally lost over 75 years.
- With POAG retinal ganglion cell loss is accelerated with a generally slow, but variable rate of loss.
- Up to 40% of optic nerve fibers need to be lost before a visual field defect appears on automated perimetry usually progressing from paracentral or mid-peripheral defect in the earlier stages to temporal visual field loss and loss of central fixation points in advanced disease.
- On comparing the mean age at presentation of patients with early relative visual field loss to those with absolute field loss within 5° of fixation, the estimated average time for untreated early disease to progress to end-stage blindness substratified by IOP levels 21–25 mm Hg, 25–30 mm Hg, and more than 30 mm Hg was 14.4 years, 6.5 years and 2.9 years, respectively.

Table 3.2: Randomized clinical trials in primary open angle glaucoma establishing the role of intraocular pressure lowering in reducing development and progression of disease.

Trial	No. of patients	Follow-up years	Study	Intervention	Outcome
OHTS	1,636	10	Eyes without POAG and IOP 24–32 mm Hg 20% IOPR	Medications	POAG risk: 4.4% treated vs. 9% untreated 10% increased risk for every mm Hg increase
CNTGS	230	7	POAG in eyes with IOP < 24 mm Hg 30% IOPR	Medications and surgery	POAG progression: 12% treated vs. 35% untreated
EMGT	255	7–11	Newly diagnosed early stage POAG. IOPR protocol driven	Betaxolol and laser trabeculoplasty or no treatment	POAG progression: 45% treated vs. 62% untreated
CIGTS	607	5+	Newly diagnosed POAG. IOPR protocol driven	Medications and surgery	No significant difference in visual field loss with initial trabeculectomy (–46%) vs. medical therapy (–38%)
AGIS	591	10–13	Advanced POAG. IOPR protocol driven	Argon laser trabeculoplasty (A) and trabeculectomy (T): ATT and TAT sequences	Visual function outcomes better with ATT in blacks and TAT in whites. Mean visual field loss 3 times greater when IOP 14.0–17.5 mm Hg vs. < 14.0 mm Hg.

(POAG: Primary open-angle glaucoma; OHTS: Ocular hypertension treatment study; IOPR: Intraocular pressure reduction; CNTGS: Collaborative normal-tension glaucoma study; EMGT: Early manifest glaucoma trial; CIGTS: Collaborative initial glaucoma treatment study; AGIS: Advanced glaucoma intervention study; ATT: Argon trabeculoplasty followed by trabeculectomy followed by trabeculectomy; TAT: Trabeculectomy followed by argon trabeculoplasty followed by trabeculectomy).

- Early manifest glaucoma trial (EMGT) has shown that progression was faster in older than in younger patients ($p = 0.002$), and those with newly diagnosed untreated pseudoexfoliative glaucoma (PXFG) (93%) compared with high-tension glaucoma (HTG) (74%) or NTG (56%) ($p = 0.012$) over 5 years. Median time to progression also differed considerably among groups: 19.5 months in pseudoexfoliation glaucoma, 44.8 months in HTG and 61.1 months in NTG (p less than 0.0001).
 - Table 3.2 enlists the trials, which show the beneficial effect of IOP lowering in reducing the disease progression.
2. A gonioscopy must be performed to rule out angle closure and a slit lamp biomicroscopy, and/or imaging studies of the ONH must be performed to document optic nerve damage. A reliable visual field is essential for diagnosing glaucoma.
 3. A pachymetry is required to give an indication of the eyes ability to withstand higher pressures. There are *no* validated nomograms for IOP correction on the basis of CCT. IOP corrected for corneal thickness, therefore, does not provide a valid basis for initiating or not initiating therapy.
 4. The threshold for starting treatment and establishing target IOP for POAG must be lower for patients with increased risk factors. These include:
 - **Race:** West Africans, Afro-Caribbeans and Hispanics have the highest predilection for disease as well as blindness
 - **Family history:** Family history of glaucoma, or glaucoma-induced blindness: a first-degree relative with POAG increases the risk 9 times, and increases the risk of disease to and 23%
 - **Age:** Younger patients

BROAD GUIDELINES FOR MANAGEMENT

The goals of treatment in POAG are to control IOP in a target range and to maintain stable optic nerves, RNFL and visual fields. The target IOP is different for each patient and is the pressure at which it is thought that the patient will not sustain further damage. Table 3.3 enlists the risk categories, which guide treatment targets.

POINTS TO REMEMBER

1. Intraocular pressure must be measured two or more times on separate occasions before labeling a patient

Table 3.3: Risk categories to guide treatment targets for primary open angle glaucoma.

Risk category*	Description	Treatment targets
High	• Moderate-advanced GON with VFD+ • Higher IOP • Rapid progression • Bilateral VFD • Pigmentary or pseudoexfoliative glaucoma • Advanced VFD or fixation threat • Glaucoma-related visual disability • Younger age	≥40% IOPR or 1–2 SD below population mean (9–12 mm Hg)
Moderate	• Mild GON with early VFD • Mild-moderate GON with low IOP • Younger age	>30% IOP reduction or population mean
Glaucoma suspect with moderate risk	• Fellow eye of established GON: excluding secondary unilateral glaucoma • OH with multiple risk factors: thin CCT, high IOP, suspicious discs • GLC gene mutations associated with severe POAG • Recurrent disc hemorrhages • Pseudoexfoliation • Younger age	Monitor closely for change or treat depending on risk and patient preferences Treat if risk(s) increase(s) with ≥20% IOP reduction or 1 SD above population mean
Glaucoma suspect with low risk	• OH • Older age • Pigment dispersion with normal IOP • Glaucoma suspect disc, including disc asymmetry • Glaucoma family history • Less important: – Steroid responder – Myopia – β-peripapillary atrophy – Diabetes mellitus – Uveitis – Systemic hypertension	Monitor

(GON: Glaucomatous optic neuropathy; VFD: Visual field defect; IOP: Intraocular pressure; IOPR: Intraocular pressure reduction; OH: Ocular hypertension; CCT: Central corneal thickness; GLC: Glaucoma; POAG: Primary open-angle glaucoma).

Source: Adapted from Asia-Pacific Glaucoma Guidelines, 2nd edition. 2008.

- *Patients with myopia:* Myopic eyes may have weaker scleral support, thus becoming more susceptible to damage, with an additional familial link between the two diseases.
 - Patients with poor access to repeat glaucoma investigations.
 - *Thin CCT:* A CCT of less than or equal to 555 µm increased the risk three times as compared with a CCT more than 588 µm. For every 40 µm decrease in CCT, the relative risk of developing POAG is 1.71
 - *Optic nerve head hemorrhage:* Disc hemorrhage increases risk of POAG 3.7 times, although most eyes with the hemorrhage (87%) may not develop POAG over 5 years (OHTS)
 - *Low Ocular Perfusion Pressure:* Diastolic ocular perfusion pressure (OPP) [diastolic blood pressure (BP) – IOP] less than 50 mm Hg may alter blood flow to the ONH and systolic OPP (systolic BP – IOP) less than or equal to 125 mm Hg is known to have a higher risk of POAG progression.
 - *Ancillary risk factors:*
 - *Genetic:* Myocilin gene (MYOC) on chromosome 1 (3–4% of POAG)
 - *Vasospasm:* Migraine, Raynaud's disease
 - Long-term steroid use
 - Obstructive sleep apnea.
5. It is important to consider the economics of glaucoma therapy as also compliance issues. Quality of life costs of treatment versus no treatment must be weighed for the individual patient.
 6. The risks and benefits of selective laser trabeculoplasty versus topical glaucoma therapy must be discussed with the patient.
 7. Advanced visual field damage must be addressed surgically whenever required. Indications for surgery are discussed later in the book.

SUGGESTED READING

1. American Academy of Ophthalmology Glaucoma Panel. (2010). Preferred practice pattern guidelines. Primary open-angle glaucoma. [online] Available from www.aao.org/ppp. [Accessed July, 2016].
2. Broman AT, Quigley HA, West SK, Katz J, Munoz B, Bandeen-Roche K, et al. Estimating the rate of progressive visual field damage among those with open-angle glaucoma from cross-sectional data. *Invest Ophthalmol Vis Sci*. 2008;49:66-76.
3. Heijl A, Bengtsson B, Hyman L, Leske MC; Early Manifest Glaucoma Trial Group. Natural history of open-angle glaucoma. *Ophthalmology*. 2009;116:2271-6.
4. Jay JL, Murdoch JR. The rate of visual field loss in untreated primary open angle glaucoma. *Br J Ophthalmol*. 1993;3:176-8.
5. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. *Arch Ophthalmol*. 2003;121:48-56.
6. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z, et al. Predictors of long-term progression in the early manifest glaucoma trial. *Ophthalmology*. 2007;114:1965-72.
7. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. *Ophthalmology*. 2001;108:1943-53.
8. South East Asia Glaucoma Interest Group. *Asia-Pacific Glaucoma Guidelines*, 2nd edition. 2008.

Clinical Cases in **Glaucoma** *An Evidence-based Approach*

Clinical Cases in Glaucoma: An Evidence-based Approach is an easy-to-read, comprehensive overview of the available evidence in current glaucoma practice. Representative cases with diagrams and pictures, as also flowcharts and algorithms for patient management, form the core structure of the manual.

The book aims to enable the student/practitioner in approaching each patient in a logical and scientific manner. It will also aid in preparing for clinical case discussions at various fora and exams. The review of literature and accompanying commentary provide useful insight and a holistic, multidisciplinary overview of glaucoma.

In the current paradigm of disease management, which is becoming increasingly focused on the evidence pyramid, *Clinical Cases in Glaucoma: An Evidence-based Approach* will be an invaluable handbook for understanding, teaching and practicing glaucoma.

Shibal Bhartiya MS is currently working as a Senior Consultant Glaucoma Surgeon, Department of Ophthalmology at Fortis Memorial Research Institute, Gurgaon, Haryana and Fortis Flt Lt Rajan Dhall Hospital, New Delhi, India. She has special interest in glaucoma diagnosis and management, and ocular surface diseases. She was a Senior Clinical Research Fellow in the Glaucoma Services, Department of Clinical Neurosciences, University of Geneva, Switzerland. Prior to that, she did her glaucoma training as Senior Research Associate in the Cornea and Glaucoma Services at Dr RP Centre for Ophthalmic Sciences, AIIMS, New Delhi, India.



She has published extensively in glaucoma, contributing several chapters to books and peer-reviewed journals alike. She has co-edited the prestigious *ISGS Textbook of Glaucoma Surgery*, *Manual of Glaucoma*, and *Practical Perimetry*, has co-authored *Living with Glaucoma*, and is the Managing Editor of the *Video Atlas of Glaucoma Surgery*.

An avid educator and researcher, she has been responsible for the design and execution of many clinical trials in both clinical and basic research. Dr. Bhartiya has lectured at, and chaired various sessions in regional and international meetings. She serves as a Reviewer for many ophthalmology journals, and is the Executive Editor of the *Journal of Current Glaucoma Practice: The Official Journal of the International Society of Glaucoma Surgery*.

Parul Ichhpujani MS is currently an Associate Professor at the Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India. She takes care of the Glaucoma and Neuro-ophthalmology services at her Center. She has done her Glaucoma training from Advanced Eye Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India, and a subsequent Clinical Research Fellowship, under Dr George L Spaeth, at Wills Eye Institute, Philadelphia, USA.



She is an avid researcher and an academician having co-authored two books, *"Pearls in Glaucoma Therapy"* and *"Living with Glaucoma"*; edited three books, *"Expert Techniques in Ophthalmology"*, *"Glaucoma: Basic and Clinical Perspectives"*, *"Manual of Glaucoma"*, and contributed several research articles and chapters in national as well as international journals and books. Dr. Ichhpujani has lectured at regional, national and international surgical meetings. She serves as a reviewer for many ophthalmology journals and is the Associate Managing Editor of the *Journal of Current Glaucoma Practice: The Official Journal of the International Society of Glaucoma Surgery*. She was enlisted in the Power List 2015 of *"Best 40 ophthalmologists under 40"*. She is a member of the Editorial Advisory Board for the year 2016-2017 for InTech Open.

**Available at all medical bookstores
or buy online at www.jaypeebrothers.com**



JAYPEE BROTHERS
Medical Publishers (P) Ltd.
www.jaypeebrothers.com

Join us on [f facebook.com/JaypeeMedicalPublishers](https://www.facebook.com/JaypeeMedicalPublishers)

Shelving Recommendation
OPHTHALMOLOGY

ISBN 978-93-86056-96-2

